WHO ART guidelines and beyond: Should CD4 count be a barrier to ART initiation  by Venter, F.
30 16th ICID Abstracts / International Journal of Infectious Diseases 21S (2014) 1–460
doned in the last decade. However a new generation of vaccines
wasborn,usingbiomolecular techniques. Called “chimerivax” tech-
nique, it uses the yellow fever (YF) 17D vaccine where the original
genes of proteins prM and E where replaced by genes coding the
proteins prM and E of each denguevirus, creating four YF virions
expressing DEN 1,2,3,4 antigens (in phase III clinical trials). Other
similar attempts have produced DEN/DEN chimeric virions, where
an attenuated serotype, is the frame of a 4-component dengue
vaccine (in phase I/II clinical trials). These vaccines show good per-
spectives of safety and immunogenicity against dengue disease.
Finally, at least two inactivated vaccines (prM and E proteins of
four serotypes) are being developed at phase I clinical trials. In
conclusion, several dengue vaccines are in the pipeline, with good
perspectives for dengue prevention.
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Mediators of vascular leak in dengue
G.N. Malavige
University of Sri Jayawardenapura, Nugegoda, Sri
Lanka
Increased vascular permeability leading to plasma leakage is
the hall mark of dengue haemorrhagic fever (DHF). The media-
tors that cause vascular leak in currently not know. As platelet
activating factor (PAF) and other lipid mediators such as sphin-
gosine 1 phosphate (S1P) are associated with increase in vascular
permeability in many disease conditions, we set out to investigate
the role of these mediators in acute dengue infection. Serum PAF,
PAF receptor, PAF-AH and SIP levels were done 45 patients with
conﬁrmed acute dengue infection and 12 healthy dengue seropos-
itive individuals. Serum PAF levels, IL-10, dengue NS1 antigen and
dengue IgG antibody levels were done in 15 patients in daily blood
samples collected throughout the course of their hospital stay. Dis-
ease severity was classiﬁed based on the WHO 2011 guidelines
for diagnosis and management of dengue infection. The effect of
PAF, PAF antagonists and serum of dengue serum on human umbil-
ical vein endothelial cell lines (HUVEC) were evaluated by confocal
microscopy. PAF levels were signiﬁcantly higher in patients with
acute dengue infection (p=0.001) when compared to healthy indi-
viduals. Although not signiﬁcant the PAF levels were higher in
those with DHF (mean 343.2, SD±437.7 ng/ml) when compared
to those with DF (mean204.7, SD±484.4 ng/ml). PAF-AH levels
were also signiﬁcantly higher in those with DHF. The PAF and IL-
10 levels were highest just before the onset of the critical phase,
which is associated with plasma leakage. In PAF levels in patients
with uncomplicated DF remained below 100ng/ml throughout
the course of the illness. The S1P levels were signiﬁcantly lower
(p =0.005) in those with DHF (mean 5.76, SD±3.1mol/l) when
compared to thosewithDF (mean11.34; SD6.1mol/l) andhealthy
individuals. Imaging studies using HUVEC cell lines showed that
ZO-1 protein was disrupted at higher concentration of PAF which
was blocked by use of a PAF antagonist. PAF levels appear to be
signiﬁcantly high in patients with acute dengue infection and SIP
signiﬁcantly lower suggesting that the delicate balance between
these mediators might have a role in the pathogenesis of vascular
leak in acute dengue.
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WHO 2013 guidelines suggest that the CD4 threshold for
antiretroviral initiation be elevated from 350 to 500 cells/ul, in
patients with HIV. This follows many (but not all) developed coun-
try guidelines, which have elevated the threshold or done away
with it altogether, based on data suggesting clinical beneﬁt, as well
as modelling studies showing signiﬁcant public health beneﬁt in
arresting new transmission. However, there has been criticism of
the new recommendation on many fronts, ranging from question-
ing of the absolute clinical beneﬁt to the individual starting early,
the extent of the HIV prevention beneﬁts of earlier initiation, to
concerns regarding the cost and operational feasibility of expand-
ing analreadyambitiousprogrammebeyondcurrentCD4strata.On
the other side, a signiﬁcant number of clinicians and public health
advocates have called for WHO to remove the CD4 threshold alto-
gether, to simplifyprogrammes, aswell asmaximise theprevention
power of antiretrovirals. This presentation will explore both sides
of the recommendation.
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Monitoring antiretroviral therapy in
resource-limited settings
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The recent WHO 2013 consolidated ART guidelines have rec-
ommended to initiated ART earlier in asymptomatic HIV-infected
individuals when CD4 count <500 cells/mm3. Several resource-
limited countries are thus implementing earlier ART. Ideally, in
settings where primary HIV resistance transmission is low and
patients are very well adhere to the treatment regimen; most
patients will have a long-term virological control regardless of VL
